An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical TrialsDavid J. Pinato, Sarah P. Blagden, Rebecca Kristeleit et al.|PLoS ONE|2014Cited by 33
Developing an objective marker to optimize patient selection and predict survival benefit in early‐phase cancer trialsChara Stavraka, Sarah P. Blagden, David J. Pinato et al.|Cancer|2013Cited by 19
Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological MalignanciesSéan M. O’Cathail, Roshan Agarwal, Janice S. Kwon et al.|International Journal of Gynecological Cancer|2013Cited by 16